European Companies Search Engine
EU funding (€7,651,315): Novel marine biomolecules against biofilm. Application to medical devices. Hor1 Apr 2015 EU Research and Innovation programme "Horizon"
Text
Novel marine biomolecules against biofilm. Application to medical devices.
Microalgae are a source of secondary metabolites useful as new bioactive compounds. Activity of these compounds against bacterial pathogens and biofilm formation has not been determined yet. Biofilm formation is especially important in infections and tissue inflammation related to implants and catheters. These problems finally cause a release of the implant, which must be removed and replaced by a new one, entailing an increase in antibiotic consumption, together with a health costs of about 50,000-90,000 € per infection episode. Taking both problems in account, the search of new antimicrobial agents that will be effective against the bacteria in their two ways of life, planktonic and biofilm stage, is a priority need in the clinical practice. For this reason, the overall objective of NOMORFILM project is to search for antibiofilm compounds isolated from microalgae that will be useful in the treatment of this kind of infections and could be incorporated in the manufacturing of medical prosthetic devices. For this purpose, 4,000 microalgae species will be deeply screened specifically for new antibacterial and antibiofilm molecules. Structural elucidation of bioactive compounds from these extracts will assure that only new chemical entities, therefore with anticipated new mechanisms of action, will arise to further project stages, those including toxicity tests and animal models. This project also addresses the biosynthesis of the targeted bioactive compounds in sustainable microalgae co-cultures, diminishing cultivation costs by mimicking natural aquatic ecosystems. Most industrially interesting antibiofilm molecules will be incorporated into nanoparticles in order to develop manufacturing methodologies able to incorporate these compounds into real prosthetic devices matrixes. Marketing of results are assured by the presence of diverse SMEs along the manufacture and distribution of prosthetic devices, and the corresponding consortium agreements with respect to IPRs
Funded Companies:
| Company name | Funding amount |
| Centre National de la Recherche Scientifique CNRS | €0.00 |
| Centro Interdisciplinar de Investigacao Marinha e Ambiental | €337,300 |
| Fotosintetica & Microbiologica Srl | €458,075 |
| Fundacion Privada Instituto de Salud Global Barcelona | €997,085 |
| Hospital Clinic de Barcelona | €0.00 |
| Karolinska Institutet | €475,000 |
| Kobenhavns Universitet | €622,285 |
| Ktedogen Srl | €633,925 |
| Mba Incorporado SL | €295,000 |
| Naicons Srl | €0.00 |
| Nanomedpharma Ltd. | €246,771 |
| Pyrogenesis SA | €729,625 |
| Sorbonne Universite | €412,375 |
| The Provost, Fellows Foundation Scholars & the Other Members of Board, of the College of the Holy & Undivided Trinity of Queen Elizabeth Near Dublin | €358,759 |
| Universidad de Almeria | €358,031 |
| Universidad de Oviedo | €575,288 |
| Universidade de Coimbra | €505,821 |
| Universita Degli Studi Di Firenze | €645,975 |
| Uppsala Universitet | €0.00 |
Source: https://cordis.europa.eu/project/id/634588
The filing refers to a past date, and does not necessarily reflect the current state.
